How Clean Is Your GLP-1?

Follow the step-by step the pathway to develop your biotherapeutic peptide

From impurity characterization to regulatory compliance, explore how robust LC and LC-MS workflows help bring biotherapeutic peptides to market faster while ensuring product quality and safety.

Join our webinar series which addresses each stage and hear expert discussions on how analytical solutions can help accelerate time to market and speed up regulatory approvals.

Step 2: How Clean Is Your GLP-1?

Purification Strategies for Peptide Development

Purification is more than a manufacturing step. It plays a critical role in product quality, impurity control, and downstream analytical success. Closely related peptide impurities can be difficult to separate, yet their characterization is essential for regulatory compliance.

Join us to learn how optimized purification workflows can improve recovery, maximize purity, and simplify downstream analytical challenges.

Why attend?

• Improve recovery of challenging GLP-1 analogues
• Isolate closely related impurities for characterization
• Obtain higher-purity fractions from limited sample quantities
• Improve efficiency throughout peptide development workflows

Key takeaway

Discover how effective purification strategies can reduce analytical risk and accelerate peptide development.

Meet the Expert(s)

Hear from Waters scientists and market experts who work with pharmaceutical manufacturers every day to solve analytical challenges across the entire GLP-1 development lifecycle, from molecule characterization and purification through to QC and regulatory readiness.

Speaker: Antonia Wierzbicki (Principal MS Market Development Manager, EMEA, Waters Corporation)

Antonia Wierzbicki is Principal Market Development Manager for Pharma in EMEA at Waters Corporation. She leads strategic initiatives focused on therapeutic peptides, GLP-1 receptor agonists, DMPK, and bioanalysis. Working closely with pharmaceutical innovators, CDMOs, and peptide manufacturers, Antonia helps organizations address analytical challenges throughout development and manufacturing. In this session, she will explore purification strategies that enable improved impurity control, greater analytical confidence, and faster GLP-1 development.